Gensaic combines AI-powered protein design with unbiased directed evolution to develop tissue-selective ligands for targeted intracellular therapeutic delivery.
The company's portfolio advances therapies for metabolic and age-related diseases, with an initial focus on siRNA payloads. FORGE™, Gensaic's proprietary product engine, integrates phage display for unbiased protein evolution within a generative AI architecture to discover and optimize protein molecules with enhanced tissue selectivity and drug-like properties.
Founded through MIT and based in Cambridge, Massachusetts, Gensaic's team of physicians, bioengineers, and machine learning scientists is advancing a singular objective: to enable selective delivery of any therapeutic payload to any tissue of interest.
For more information, please visit gensaic.com.
Company Details
- Employees
- 12
- Founded
- 2021
- Address
- Cambridge, Massachusetts 02139, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.gensaic.com
- HQ
- Cambridge, Massachusetts
Gensaic Questions
Gensaic's website is http://www.gensaic.com
Gensaic's LinkedIn profile is https://www.linkedin.com/company/gensaic
Gensaic has
12 employees.
View email and phone details for 12
employees at Gensaic.
Gensaic's industry is
Biotechnology Research
Gensaic's top competitors are
Bioage Labs,
Noetik,
Labcentral,
Inceptive,
Bioptimus,
Enveda,
Novo Nordisk,
Terray Therapeutics,
Mana.bio,
Tahoe Therapeutics.
Gensaic's categories are Biotechnology Research
Gensaic's founding year is 2021
